Get access to our best features
Get Started
Subscribe
Israel-Hamas Conflict
Met Gala
Stormy Daniels
Donald Trump
Tornado
US Social Issues
US Politics
Joe Biden
US Economy
Republican Party
Baseball
Apple
Artificial Intelligence
Get access to our best features
Get Started
Published 27 days ago

Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says - Vaxcyte (NASDAQ:PCVX)

Summary by Benzinga
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the US discussing vaccination age reduction. Prevnar20 dominates with 97% market share in adults, but Vaxcyte's advanced conjugate capabilities present a competitive advantage. Latest Ratings for PCVX DateFirmActionFromTo Jul 2020NeedhamInitiates Cov…

0 Articles

All
Left
Center
Right
BenzingaBenzinga

Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says - Vaxcyte (NASDAQ:PCVX)

The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the US discussing vaccination age reduction. Prevnar20 dominates with 97% market share in adults, but Vaxcyte's advanced conjugate capabilities present a competitive advantage. Latest Ratings for PCVX DateFirmActionFromTo Jul 2020NeedhamInitiates Cov…

27 days ago·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

PfizerPfizer
MerckMerck
Trending Topics
Ground News logo
US
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc.
News
For You
Search
BlindspotLocal